REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 189 filers reported holding REATA PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 0.71 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $8,642,639 | +181.5% | 56,649 | +67.8% | 0.01% | +175.0% |
| Q1 2023 | $3,069,823 | +175.9% | 33,764 | +15.3% | 0.00% | +100.0% |
| Q4 2022 | $1,112,461 | -99.9% | 29,283 | -52.5% | 0.00% | 0.0% |
| Q3 2022 | $1,549,265,000 | -37.8% | 61,650 | -24.8% | 0.00% | -50.0% |
| Q2 2022 | $2,491,129,000 | +33.3% | 81,972 | +43.7% | 0.00% | +33.3% |
| Q1 2022 | $1,868,434,000 | +105.7% | 57,034 | +65.6% | 0.00% | +200.0% |
| Q4 2021 | $908,236,000 | -58.9% | 34,442 | +56.8% | 0.00% | -66.7% |
| Q3 2021 | $2,209,295,000 | +161.5% | 21,959 | +267.8% | 0.00% | +200.0% |
| Q2 2021 | $844,934,000 | +650.6% | 5,970 | +428.8% | 0.00% | – |
| Q1 2021 | $112,561,000 | +13.7% | 1,129 | +40.9% | 0.00% | – |
| Q4 2020 | $99,020,000 | +111.8% | 801 | +66.9% | 0.00% | – |
| Q3 2020 | $46,762,000 | -95.6% | 480 | -93.0% | 0.00% | -100.0% |
| Q2 2020 | $1,072,325,000 | -1.1% | 6,873 | -8.5% | 0.00% | 0.0% |
| Q1 2020 | $1,084,282,000 | +67.2% | 7,512 | +136.8% | 0.00% | +100.0% |
| Q4 2019 | $648,452,000 | +119.3% | 3,172 | -13.9% | 0.00% | 0.0% |
| Q3 2019 | $295,628,000 | +22.3% | 3,682 | +43.8% | 0.00% | – |
| Q2 2019 | $241,630,000 | -35.5% | 2,561 | -41.6% | 0.00% | -100.0% |
| Q1 2019 | $374,786,000 | +3653.1% | 4,385 | +2363.5% | 0.00% | – |
| Q4 2018 | $9,986,000 | -84.1% | 178 | -76.8% | 0.00% | – |
| Q3 2018 | $62,710,000 | +207.6% | 767 | +31.6% | 0.00% | – |
| Q2 2018 | $20,388,000 | -59.5% | 583 | -76.3% | 0.00% | – |
| Q1 2018 | $50,373,000 | -26.3% | 2,456 | +1.8% | 0.00% | – |
| Q4 2017 | $68,308,000 | +157.5% | 2,412 | +182.8% | 0.00% | – |
| Q3 2017 | $26,528,000 | -9.4% | 853 | -7.8% | 0.00% | – |
| Q2 2017 | $29,267,000 | +1420.4% | 925 | +988.2% | 0.00% | – |
| Q1 2017 | $1,925,000 | -67.9% | 85 | -69.1% | 0.00% | – |
| Q4 2016 | $6,003,000 | -42.3% | 275 | -30.4% | 0.00% | – |
| Q3 2016 | $10,412,000 | +134.3% | 395 | +75.6% | 0.00% | – |
| Q2 2016 | $4,444,000 | – | 225 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Conrad N. Hilton Foundation | 63,481 | $7,847,000 | 100.00% |
| CPMG Inc | 2,896,901 | $358,115,000 | 55.16% |
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 140,000 | $17,307,000 | 26.62% |
| Corriente Advisors, LLC | 525,000 | $64,901,000 | 15.45% |
| DUMAC, INC. | 76,050 | $9,401,000 | 7.33% |
| MADDEN SECURITIES Corp | 35,152 | $4,345,000 | 2.80% |
| Biondo Investment Advisors, LLC | 113,692 | $14,055,000 | 2.69% |
| Duquesne Family Office | 749,897 | $92,702,000 | 2.50% |
| LBJ Family Wealth Advisors, Ltd. | 30,368 | $3,754,000 | 2.44% |
| Integral Health Asset Management, LLC | 50,000 | $6,181,000 | 1.84% |